Our lead program, ASN100, is being studied to prevent hospital-acquired Staphylococcus aureus pneumonia in mechanically-ventilated patients who are heavily-colonized with Staphylococcus aureus.
Arsanis is studying ASN200 to potentially combat infections caused by multi-drug resistant strains of the Gram-negative pathogen Escherichia coli.
Arsanis is developing ASN300 to address infections caused by multi-drug resistant strains of the Gram-negative pathogen Klebsiella pneumoniae.
The ASN400 program is currently in the discovery phase and is designed to counteract important virulence mechanisms of Streptococcus pneumoniae.
The ASN500 program, comprised of highly potent mAbs targeting RSV, is currently in the discovery phase. Arsanis received a $9.3 million grant from the Bill & Melinda Gates Foundation to take an initial RSV candidate through to IND filing.